Biosimilar switch study aims to keep chronic conditions in check
Disease control
Recruiting now
This study follows 225 adults with chronic spontaneous urticaria (long-term hives) or severe allergic asthma whose disease has been stable for at least 3 months on the original omalizumab. Their doctor has decided to switch them to a biosimilar version called Omlyclo®. The main g…
Sponsor: Celltrion HealthCare France • Aim: Disease control
Last updated May 26, 2026 11:52 UTC